Synairgen shares to trade on Asset Match platform

SOUTHAMPTON, UK - Synairgen PLC (LON:SYNG), a biotech firm focused on respiratory diseases, has announced that its Ordinary Shares will be admitted to trading on the Asset Match platform, with the first auction scheduled for September 2025. Asset Match provides an electronic off-market dealing facility that matches buyers and sellers in periodic auctions, offering an alternative trading venue for the company’s shares following its delisting from the AIM market.

The trading of Synairgen’s shares on Asset Match is designed to provide liquidity for shareholders and enable new investors to participate. Auctions are expected to occur semiannually, and details regarding the trading process are available on Synairgen’s and Asset Match’s websites.

Joseph Colliver, CFO of Synairgen, expressed satisfaction with the partnership, stating that the platform will facilitate straightforward trading for the company’s shares as it continues operations as a private entity. Ben Weaver of Asset Match welcomed Synairgen to the platform, underscoring the opportunity for shareholders to achieve periodic liquidity.

This move comes as Synairgen continues the development of SNG001, an inhaled formulation containing interferon beta, which is currently under investigation as a broad-spectrum antiviral treatment. The company’s transition to Asset Match reflects a strategy to maintain shareholder engagement and market presence outside the traditional exchange environment.

Shareholders seeking to trade Synairgen shares via Asset Match can direct their inquiries to the email provided by the platform. This announcement is based on a press release statement issued by Synairgen PLC.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.